The device uses electromagnetic waves to target tumors and is available to patients for whom first- and second-line ...

Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

PLEK2 has been found to promote the progression and metastasis of some tumors, but its role in UVM has not yet been reported. Through this study, we hope to explore the effect of PLEK2 on the ...

Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.

Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...

The trillions of microbial cells in our gastrointestinal tract have their own genomes and metabolic products, many of which ...

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either ...

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 ...

T-DXd improves progression-free survival vs physician’s choice, regardless of time to progression or endocrine resistance, in ...

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver ...

Overall survival at 5 years for individuals who received a liver transplant for certain cancers is deemed adequate.